Ionis Pharmaceuticals Inc. (IONS)

63.11
NASDAQ : Health Technology
Prev Close 64.78
Day Low/High 62.27 / 64.70
52 Wk Low/High 43.27 / 86.58
Avg Volume 1.05M
Exchange NASDAQ
Shares Outstanding 140.50M
Market Cap 9.10B
EPS 2.10
P/E Ratio 21.74
Div & Yield N.A. (N.A)

Latest News

Ionis Licenses Hepatitis B Program To GSK

Ionis Licenses Hepatitis B Program To GSK

- GSK exercises option to license program following positive Phase 2 results

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CHUY, CNNE, CODI, CUB, GWRS, PLOW, SBRA, WK Downgrades: AC, AVT, CECO, GDOT, GMRE, HMLP, INVA, IONS, IVR, MPAA, MUFG, NKTR, PPIH, QDEL, TGE, TRUE, UVV, WES, WMGI Initiations: AVLR Read on to get TheStreet Quant Ratings' detailed report:

Ionis Reports Second Quarter 2019 Financial Results

Ionis Reports Second Quarter 2019 Financial Results

Q2 2019 year-to-date revenues increased more than 75% to $461 million

Ionis Pharmaceuticals Larger Than S&P 500 Component WestRock

Ionis Pharmaceuticals Larger Than S&P 500 Component WestRock

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Ionis Pharmaceuticals Inc was identified as having a larger market cap than the smaller end of the S&P 500, for example WestRock Co , according to The Online Investor. Market capitalization is an important data point for investors to keep an eye on, for various reasons.

Ionis Pharmaceuticals To Hold Second Quarter 2019 Financial Results Webcast

Ionis Pharmaceuticals To Hold Second Quarter 2019 Financial Results Webcast

Webcast scheduled for Wednesday, August 7th at 11:30 a.m. Eastern Time

Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) As A Foundation Of Care In Spinal Muscular Atrophy For A Broad Range Of Patients

Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) As A Foundation Of Care In Spinal Muscular Atrophy For A Broad Range Of Patients

- New results from the NURTURE study demonstrate that pre-symptomatic infants treated with SPINRAZA are achieving motor milestones that are unprecedented in the natural history of the disease, including 100 percent of children sitting without support and 88 percent walking independently

Ionis Pharmaceuticals To Present At The BMO Prescription For Success Healthcare Conference

Ionis Pharmaceuticals To Present At The BMO Prescription For Success Healthcare Conference

CARLSBAD, Calif., June 18, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc.

Ionis Announces Appointment Of Joan E. Herman To Its Board Of Directors

Ionis Announces Appointment Of Joan E. Herman To Its Board Of Directors

CARLSBAD, Calif., June 12, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals To Provide Corporate Update And 30-year Retrospective At Its 2019 Annual Meeting Of Stockholders

Ionis Pharmaceuticals To Provide Corporate Update And 30-year Retrospective At Its 2019 Annual Meeting Of Stockholders

CARLSBAD, Calif., June 6, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc.

Ionis Reports First Quarter 2019 Financial Results

Ionis Reports First Quarter 2019 Financial Results

Revenues more than doubled compared to 2018, resulting in net income of $84 million

Ionis Launches New Corporate Brand That Reflects Company's Industry-leading Innovation And Unique Culture Of Saying "yes" To Patients

Ionis Launches New Corporate Brand That Reflects Company's Industry-leading Innovation And Unique Culture Of Saying "yes" To Patients

CARLSBAD, Calif., May 6, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc.

Positive Clinical Data At AAN 2019 Reinforces Ionis' Commitment To Delivering Life-changing Medicines To Patients With Neurological Diseases

Positive Clinical Data At AAN 2019 Reinforces Ionis' Commitment To Delivering Life-changing Medicines To Patients With Neurological Diseases

Twelve presentations highlighting transformational medicines for SMA, hATTR, Huntington's disease, ALS, prion disease and others

Ionis Pharmaceuticals To Hold First Quarter 2019 Financial Results Webcast

Ionis Pharmaceuticals To Hold First Quarter 2019 Financial Results Webcast

Webcast scheduled for Thursday, May 9th at 11:30 a.m. Eastern Time

10 Speculative Stock Plays in the Biotech Sector

10 Speculative Stock Plays in the Biotech Sector

For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.

Ionis Pharmaceuticals To Provide Corporate Update At 2019 Annual Meeting Of Stockholders

Ionis Pharmaceuticals To Provide Corporate Update At 2019 Annual Meeting Of Stockholders

CARLSBAD, Calif., April 8, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc.

Ionis Announces Appointment Of Brett P. Monia Ph.D. To Its Board Of Directors

Ionis Announces Appointment Of Brett P. Monia Ph.D. To Its Board Of Directors

CARLSBAD, Calif., March 25, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ALRM, ATRS, CCK, CGC, FHN, FLGT, FND, GIFI, GTS, IMKTA, IONS, IROQ, LAWS, LEG, MANH, MOFG, NMFC, NPTN, NWN, RUN, VAC, WAL, XRAY Downgrades: ACHC, CNCE, HCI, ORBC, VMW Initiations: ALTR, FNKO, SE Read on to get TheStreet Quant Ratings' detailed report:

How to Fatten Up Your Portfolio By Investing in the Obesity Epidemic

How to Fatten Up Your Portfolio By Investing in the Obesity Epidemic

As the U.S. and the world grow fatter, some investors are seeing green as they bulk up on stocks of companies on the front-lines of this 21st century Battle of the Bulge.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ACIW, AEYE, HTA, IONS Downgrades: BCBP, DWSN, JAX, KORS Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Interesting IONS Put And Call Options For September 21st

Interesting IONS Put And Call Options For September 21st

Investors in Ionis Pharmaceuticals Inc saw new options become available this week, for the September 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the IONS options chain for the new September 21st contracts and identified one put and one call contract of particular interest.

Ionis Pharmaceuticals Larger Than S&P 500 Component Leggett & Platt

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Ionis Pharmaceuticals Inc was identified as having a larger market cap than the smaller end of the S&P 500, for example Leggett & Platt, Inc. , according to The Online Investor.

Alibaba, First American, Coherent: 'Mad Money' Lightning Round

Alibaba, First American, Coherent: 'Mad Money' Lightning Round

Jim Cramer makes the calls on Alibaba, First American, Coherent, Ionis Pharmacuetical, Skechers USA, Corning, Bank of Internet and more.

Where's the Real Leadership?: Cramer's 'Mad Money' Recap (Monday 4/30/18)

Where's the Real Leadership?: Cramer's 'Mad Money' Recap (Monday 4/30/18)

Love the banks, then hate the banks. Love the industrials? Nope, they're out, too. Jim Cramer says it's ugly, but he would use the weakness in the upside surprises.

Biogen And Ionis Expand Strategic Collaboration To Develop Drug Candidates For A Broad Range Of Neurological Diseases

Biogen And Ionis Expand Strategic Collaboration To Develop Drug Candidates For A Broad Range Of Neurological Diseases

Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals (Nasdaq: IONS) announced today they have expanded their strategic collaboration through a new ten-year collaboration agreement to develop novel antisense drug candidates for a broad range of neurological...

Video: Jim Cramer Reacts to Novartis' Acquisition of AveXis

Video: Jim Cramer Reacts to Novartis' Acquisition of AveXis

Novartis agreed to acquire AveXis for $8.7 billion on Monday. TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts.

New Data Presented At MDA Clinical Conference Show Benefit In Motor Function For Infants, Teens And Young Adults Treated With SPINRAZA® (nusinersen)

New Data Presented At MDA Clinical Conference Show Benefit In Motor Function For Infants, Teens And Young Adults Treated With SPINRAZA® (nusinersen)

Biogen (Nasdaq: BIIB) today announced new interim Phase 2 results from NURTURE, the ongoing open-label, single-arm study evaluating the efficacy and safety of SPINRAZA ® (nusinersen) among pre-symptomatic...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: EOG, FGEN, GASS, GHC, SATS Downgrades: ALB, CFBK, CLI, DISCB, FORM, HCCI, IONS, KOP, LTC, MNRO, PNTR, SRE Initiations: FRAC, JELD, REVG Read on to get TheStreet Quant Ratings' detailed report:

TheStreet Quant Rating: C (Hold)